6 completed, 5 unknown, 1 active not recruiting, 1 not yet recruiting. 7 Phase 3, 5 Phase 2, 2 Not applicable, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Unknown 2, Active not recruiting 1 |
| Phase 2 | 5 | Unknown 3, Recruiting 1, Terminated 1 |
| Not applicable | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow PE regimen: new trials by email Literature Review of PE regimen trials Research Report on PE regimen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel - Solid Tumor Cancer, Chemotherapy Induced Neutropenia | Not applicable | Not yet recruiting | Shandong Cancer Hospital and Institute | 200 | 2024-10-10 | 2024-10-18 |
| A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer HLX10, carboplatin/cisplatin-etoposide, Thoracic radiotherapy - Limited-Stage Small Cell Lung Cancer | Phase 3 | Active not recruiting | Shanghai Henlius Biotech | 511 | 2022-05-17 | 2026-01-13 |
| Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer Surufatinib,Etoposide,Cisplatin,Toripalimab, Surufatinib,Etoposide,Cisplatin - Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 88 | 2021-11-09 | 2022-11-14 |
| The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors Whole-ventricle irradiation, Carboplatin/etoposide, Ifosfamide/cisplatin/etoposide - Intracranial Germ Cell CNS Tumor, Childhood | Phase 2 | Recruiting | Beijing Tiantan Hospital | 150 | 2021-09-15 | 2021-11-18 |
| Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer Camrelizumab, Fluzoparib, Cisplatin，Pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 65 | 2021-03-01 | 2021-05-11 |
| Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma Simmtecan, 5-FU and l-LV, Toripalimab, Etoposide, Cisplatin - Neuroendocrine Carcinoma of the Bladder | Phase 2 / Phase 3 | Unknown | Peking University | 336 | 2019-06-19 | 2019-06-20 |
| Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer Durvalumab, Placebo, Cisplatin/ Etoposide - Non-Small Cell Lung Cancer | Phase 3 | Completed | AstraZeneca | 328 | 2018-03-29 | 2026-07-14 |
| Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma irinotecan cisplatin, Etoposide cisplatin - Neuroendocrine Carcinoma | Phase 2 | Terminated | Peking University | 66 | 2017-04-29 | 2020-01-22 |
| A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer cisplatin, etoposide, cisplatin, etoposide, apatinib - Progression Free Survival | Phase 3 | Unknown | Qingdao University | 120 | 2017-03-01 | 2017-04-04 |
| Molecular Phenotype Changes and Personalized Treatment for CRPC Docetaxel & Prednisone, DP & Targeted drugs, cisplatin & Etoposide - Hormone Refractory Prostate Cancer | Not applicable | Unknown | Tianjin Medical University Cancer Institute and Hospital | 150 | 2014-06-01 | 2014-08-05 |
| A Study Evaluating the Safety of ABT-263 in Combination With Etoposide/Cisplatin in Subjects With Cancer ABT-263, etoposide/cisplatin - Solid Tumors | Phase 1 | Completed | AbbVie (prior sponsor, Abbott) | 12 | 2009-10-01 | 2018-06-06 |
| Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer Etoposide + cisplatin, Irinotecan + cisplatin - Small Cell Lung Carcinoma | Phase 3 | Completed | Pfizer | 485 | 2002-06-01 | 2010-02-18 |
| Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults topotecan/cisplatin, etoposide/cisplatin - Small Cell Lung Cancer | Phase 3 | Completed | GlaxoSmithKline | 760 | 2001-04-01 | 2013-08-21 |
| Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer Cisplatin + etoposide, Epirubicin + ifosfamide + etoposide - Small Cell Lung Carcinoma, Extensive Disease | Phase 3 | Completed | European Lung Cancer Working Party | 361 | 2000-04-01 | 2015-02-12 |
| PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases ifosfamide - Small Cell Lung Cancer | Completed | Azienda USL Reggio Emilia - IRCCS | 46 | 1998-12-01 | 2025-06-11 |
Small Cell Lung Carcinoma (6) · Carcinoma, Neuroendocrine (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma (1)
Peking University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · AbbVie (prior sponsor, Abbott) (1) · AstraZeneca (1) · Azienda USL Reggio Emilia - IRCCS (1) · Beijing Tiantan Hospital (1) · European Lung Cancer Working Party (1) · GlaxoSmithKline (1) · Pfizer (1) · Qingdao University (1) · Shandong Cancer Hospital and Institute (1) · Shanghai Henlius Biotech (1) · Sun Yat-sen University (1)
China (10) · Czechia (4) · Poland (4) · Spain (4) · Austria (3) · Belgium (3) · France (3) · Germany (3) · Hungary (3) · Netherlands (3) · Russia (3) · United States (3) · Brazil (2) · Greece (2) · Italy (2)
Jean-Paul Sculier, MD, PhD (1) · Jeffrey Bradley, MD (1) · JinMing Yu, Phd (1) · Jinming Yu, MD (1) · Lin Shen (1) · Mack Mabry, MD (1) · Tao Jiang, MD, PhD (1) · Wang HaiTao, Ph.D (1) · Ying Cheng (1) · Zhuang Yu, MD, Ph. D (1)
PMID 25903963, PMID 28975084, PMID 39327433
2017 (1)